Antibody Drug Conjugates for Cancer Therapy

By Paul Polakis. Pharmacological Reviews, 2016

929 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/5dcc3707f122df06520e624eb4db319c4c52a275

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Paul Polakis

In Radiology, Nuclear Medicine and Imaging

1. Paul Polakis
2. S. Bhakta
3. S. Panowski
4. Jagath R Junutula
5. H. Raab

Citations in the corpus

• Site-specific antibody drug conjugates for cancer therapy (2013, background): “The cytotoxins are highly potent, with free drug IC 50 of 10-9 M, and ADCs that incorporate these agents have been explored in the clinic, including inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate developed by Pfizer, and MDX-1203, an anti-CD70duocarmycin developed by Bristol-Myers Squi”